Pfizer, which is providing 17 licensed drug assets to the immuno-oncology startup, will own a 25% stake once the series A round formally closes.
US-based immuno-oncology drug developer Allogene Therapeutics has launched with $300m in series A financing from investors including pharmaceutical firm Pfizer, which is also providng assets for the startup.
The round was also backed by University of California’s Office of the Chief Investment Officer of the Regents as well as private equity group TPG, life sciences-focused venture capital firm Vida Ventures and BellCo Capital.
Pfizer will own a 25% equity stake in Allogene following the deal, which is expected to close…
